Answers are grounded in this paper and cite their sources.
Autoimmune hepatitis (AIH) is a heterogeneous group of diseases of unknown cause, characterized by necro-inflammatory hepatocellular lesions, the presence of specific autoantibodies, and high sensitivity to corticosteroids [1]. The clinical presentation of AIH is heterogeneous; nearly one-third of patients are asymptomatic, and in 25% of cases, cirrhosis is present at diagnosis [5]. Clinical manifestations can range from mild or severe symptoms to fulminant liver failure [6], with up to 40% of patients presenting with acute hepatitis [7]. The aim of our study is to describe its epidemiological and therapeutic aspects.
No takes yet. Share an insight, caveat, or question.
Malki et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: